Cosciens Biopharma Files November 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Nov 14, 2025 · CIK: 1113423
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, company-update
TL;DR
Cosciens Biopharma (fka Aeterna Zentaris) filed its monthly 6-K, standard foreign issuer update.
AI Summary
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on November 14, 2025. The filing is a report of a foreign private issuer for the month of November 2025. The company's principal executive office is located in Toronto, Ontario, Canada.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding the company's status as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- Toronto (location) — Business address city
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.
When was this Form 6-K filed?
This Form 6-K was filed on November 14, 2025.
What is the current name of the company filing this report?
The current name of the company is COSCIENS Biopharma Inc.
What was the company's former name?
The company's former name was Aeterna Zentaris Inc.
Where is the company's principal executive office located?
The company's principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Filing Stats: 982 words · 4 min read · ~3 pages · Grade level 15.6 · Accepted 2025-11-14 17:15:12
Filing Documents
- form6-k.htm (6-K) — 32KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-023633.txt ( ) — 53KB
forward-looking statements
forward-looking statements. Forward-looking synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: the Company’s patented technologies and value-driving products, and development thereof; the extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related products; the successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan from yeast, as well as such products’ capability to address unmet needs within the nutraceuticals markets; Macrilen® (macimorelin) and the Company’s plans in respect of same, including commercialization. the Company’s business strategy; the strategic decision to sunset the Company’s Amyotrophic Lateral Sclerosis (ALS), AIM Biologicals and Delayed Clearance Parathyroid Hormone (DC-PTH) programs ; the transition to a new presidential administration in the United States, including the potential use and effects of tariffs to address the administration’s policy goals, could materially impact our costs and revenues, as well as the macroeconomic framework in which we operate. the Company’s positioning in its target markets; the Company’s ability to accelerate the scale-up of PGX Technology towards commercial levels; expectations for completion of the Company’s Edmonton facility and Natex Termitz facility; pre-clinical and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market following such studies and trials; the ab